Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Yaffe, K. Articles by Grady, D. Search for Related Content PubMed Citation Articles by Yaffe, K. Articles by Grady, D. Gender Geriatric Psychiatry Alzheimer's Disease Dementias (General) Other Somatic Therapy Cognition

Effect of Raloxifene on Prevention of Dementia and Cognitive Impairment in Older Women: The Multiple Outcomes of Raloxifene Evaluation (MORE) Randomized Trial

OBJECTIVE: This investigation examined whether raloxifene, a selective estrogen receptor modulator, affects the risk for Alzheimer’s disease. METHOD: The Multiple Outcomes of Raloxifene Evaluation was a randomized, placebo-controlled trial among postmenopausal women with osteoporosis. The effect of raloxifene (60 or 120 mg/day) on vertebral fractures was the primary outcome. Development of mild cognitive impairment and dementia was a secondary outcome. Women were given clinical and cognitive evaluations at baseline and annually. After 3 years, among the 5,386 women enrolled at participating sites, those who had clinical symptoms of dementia or scored in the lowest 10th percentile on cognitive screening were evaluated by a blinded dementia specialist and had brain scans and laboratory tests to evaluate dementia etiology. Dementia was diagnosed by a blinded adjudication committee. RESULTS: Of the 5,386 women, 5,153 (95.7%) were classified as cognitively normal, 181 (3.4%) had mild cognitive impairment, and 52 (1.0%) had dementia, 36 with Alzheimer’s disease. Compared to those taking placebo, women receiving 120 mg/day of raloxifene had a 33% lower risk of mild cognitive impairment (relative risk, 0.67; 95% confidence interval [CI], 0.46–0.98) and somewhat lower risks of Alzheimer’s disease (relative risk=0.52, 95% CI=0.22–1.21) and any cognitive impairment (relative risk=0.73, 95% CI=0.53–1.01). Risks of mild cognitive impairment, Alzheimer’s disease, and any impairment were not significantly different in the group taking 60 mg/day of raloxifene. CONCLUSIONS: Raloxifene at a dose of 120 mg/day, but not 60 mg/day, resulted in reduced risk of cognitive impairment in postmenopausal women.

This article has been cited by other articles:

				K. Visvanathan, R. T. Chlebowski, P. Hurley, N. F. Col, M. Ropka, D. Collyar, M. Morrow, C. Runowicz, K. I. Pritchard, K. Hagerty, et al. American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction J. Clin. Oncol., July 1, 2009; 27(19): 3235 - 3258. [Abstract] [Full Text] [PDF]

				K. Yaffe, A. L. Weston, T. Blackwell, and K. A. Krueger The Metabolic Syndrome and Development of Cognitive Impairment Among Older Women Arch Neurol, March 1, 2009; 66(3): 324 - 328. [Abstract] [Full Text] [PDF]

				N. Scarmeas, Y. Stern, R. Mayeux, J. J. Manly, N. Schupf, and J. A. Luchsinger Mediterranean Diet and Mild Cognitive Impairment Arch Neurol, February 1, 2009; 66(2): 216 - 225. [Abstract] [Full Text] [PDF]

				A. Peri and M. Serio Neuroprotective effects of the Alzheimer's disease-related gene seladin-1 J. Mol. Endocrinol., November 1, 2008; 41(5): 251 - 261. [Abstract] [Full Text] [PDF]

				J. C. Carroll and C. J. Pike Selective Estrogen Receptor Modulators Differentially Regulate Alzheimer-Like Changes in Female 3xTg-AD Mice Endocrinology, May 1, 2008; 149(5): 2607 - 2611. [Abstract] [Full Text] [PDF]

				K. Yaffe Antioxidants and Prevention of Cognitive Decline: Does Duration of Use Matter? Arch Intern Med, November 12, 2007; 167(20): 2167 - 2168. [Full Text] [PDF]

				J. H. Morrison, R. D. Brinton, P. J. Schmidt, and A. C. Gore Estrogen, Menopause, and the Aging Brain: How Basic Neuroscience Can Inform Hormone Therapy in Women J. Neurosci., October 11, 2006; 26(41): 10332 - 10348. [Full Text] [PDF]

				J. L. Turgeon, M. C. Carr, P. M. Maki, M. E. Mendelsohn, and P. M. Wise Complex Actions of Sex Steroids in Adipose Tissue, the Cardiovascular System, and Brain: Insights from Basic Science and Clinical Studies Endocr. Rev., October 1, 2006; 27(6): 575 - 605. [Abstract] [Full Text] [PDF]

				S. R. Land, D. L. Wickerham, J. P. Costantino, M. W. Ritter, V. G. Vogel, M. Lee, E. R. Pajon, J. L. Wade III, S. Dakhil, J. B. Lockhart Jr, et al. Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial JAMA, June 21, 2006; 295(23): 2742 - 2751. [Abstract] [Full Text] [PDF]

				K Alagiakrishnan, P McCracken, and H Feldman Treating vascular risk factors and maintaining vascular health: Is this the way towards successful cognitive ageing and preventing cognitive decline? Postgrad. Med. J., February 1, 2006; 82(964): 101 - 105. [Abstract] [Full Text] [PDF]

				Emerging Perspectives: New Ways to Predict and Treat Alzheimer Disease Journal Watch Psychiatry, May 18, 2005; 2005(518): 4 - 4. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 2005 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us